Application 022064
- Type
- NDA
- Sponsor
- SANOFI AVENTIS US
Application Products#
| Product | Drug | Ingredient | Form | Strength | Reference drug | Reference standard |
|---|---|---|---|---|---|---|
| 001 | XYZAL | LEVOCETIRIZINE DIHYDROCHLORIDE | TABLET;ORAL | 5MG | Yes | Yes |
NDC Listings For This Application#
| NDC | Name | Nonproprietary name | Labeler | Marketing category | Status |
|---|---|---|---|---|---|
| 0024-5803 | Xyzal | levocetirizine dihydrochloride | Sanofi-Aventis U.S. LLC | NDA | Current |
| 0024-5803 | Xyzal | levocetirizine dihydrochloride | Sanofi-Aventis U.S. LLC | NDA | Current |
| 0024-5803 | Xyzal | levocetirizine dihydrochloride | Sanofi-Aventis U.S. LLC | NDA | Current |
Documents#
| Document | Submission type | Date |
|---|---|---|
| 82832 | SUPPL | 2025-07-14 |
| 82828 | SUPPL | 2025-07-14 |
| 58214 | SUPPL | 2019-04-04 |
| 58195 | SUPPL | 2019-04-03 |
| 57254 | SUPPL | 2019-01-18 |
| 57232 | SUPPL | 2019-01-16 |
| 53596 | SUPPL | 2018-04-03 |
| 53595 | SUPPL | 2018-04-03 |
| 50116 | SUPPL | 2017-10-19 |
| 50065 | SUPPL | 2017-10-17 |
| 48970 | SUPPL | 2017-07-13 |
| 48963 | SUPPL | 2017-07-13 |
| 47234 | SUPPL | 2017-02-16 |
| 47166 | SUPPL | 2017-02-10 |
| 45859 | SUPPL | 2016-11-09 |
| 45856 | SUPPL | 2016-11-09 |
| 38173 | SUPPL | 2016-06-27 |
| 29183 | SUPPL | 2016-06-24 |
| 38172 | SUPPL | 2013-11-08 |
| 6801 | SUPPL | 2013-11-08 |
| 38171 | SUPPL | 2012-09-11 |
| 6800 | SUPPL | 2012-09-07 |
| 6799 | SUPPL | 2011-03-10 |
| 16872 | SUPPL | 2011-03-07 |
| 6798 | SUPPL | 2009-11-10 |
| 38170 | SUPPL | 2009-10-06 |
| 52313 | ORIG | 2009-08-25 |
| 44671 | ORIG | 2008-10-15 |
| 42405 | ORIG | 2008-10-15 |
| 16869 | ORIG | 2008-04-09 |
| 6796 | ORIG | 2008-04-09 |
| 29182 | SUPPL | 2008-04-02 |
| 16871 | SUPPL | 2008-04-01 |
| 16870 | SUPPL | 2008-02-14 |
| 6797 | SUPPL | 2008-02-05 |
| 53311 | ORIG | 1900-01-01 |
| 53310 | ORIG | 1900-01-01 |